Abstract
Aldosterone is a vitally important factor in cardiovascular homeostasis. Tightly regulated control of the biosynthesis and action of this mineralocorticoid hormone are crucial given that its excessive secretion, as seen in primary aldosteronism (PA), can result in severe hypertension, extensive organ damage and various comorbidities. The individual and societal consequences of this are huge: PA is currently held to account for ~15% of all hypertensive patients, but, due to difficulties in its accurate diagnosis, even this figure is likely to be an underestimate. Many patients are therefore currently classified as essential hypertensives and are receiving suboptimal treatment. Greater understanding of the regulatory systems governing aldosterone biosynthesis and action is therefore likely to be of huge benefit, leading to improved diagnostics, identification of informative biomarkers and development of better treatments more accurately targeted at the sizeable subsection of hypertensive patients most likely to benefit.
In this article we describe the major factors governing aldosterone biosynthesis and action in normal physiology and disease while also summarising significant recent advances in our understanding of PA and other promising current areas of research. It is our intention that this will provide insights into the highly dynamic state of current aldosterone research and the very real potential for game-changing treatments to counter the causes and consequences of excess aldosterone in the near future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Connell JMC, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008;29:133–54.
Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81–151.
Bollag WB. Regulation of aldosterone synthesis and secretion. Compr Physiol. 2014;4:1017–55.
Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev. 2016;96:1327–84.
MacKenzie SM, Freel EM, Connell JM, Fraser R, Davies E. ACTH and polymorphisms at steroidogenic loci as determinants of aldosterone secretion and blood pressure. Int J Mol Sci. 2017;18:579.
Markou A, Sertedaki A, Kaltsas G, et al. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab. 2015;100:2857–64.
MacKenzie SM, Connell JMC, Davies E. Non-adrenal synthesis of aldosterone: a reality check. Mol Cell Endocrinol. 2011;350:163–7.
Takeda Y, Demura M, Wang F, et al. Epigenetic regulation of aldosterone synthase gene by sodium and angiotensin II. J Am Heart Assoc. 2018;7:e008281.
Robertson S, MacKenzie SM, Alvarez-Madrazo S, Diver LA, Lin J, Stewart PM, Fraser R, Connell JM, Davies E. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension. 2013;62:572–8.
Lenzini L, Caroccia B, Campos AG, et al. Lower expression of the TWIK-related acid-sensitive K+ channel 2 (TASK-2) gene is a hallmark of aldosterone-producing adenoma causing human primary aldosteronism. J Clin Endocrinol Metab. 2014;99:E674–82.
Baker ME, Katsu Y. Evolution of the mineralocorticoid receptor: sequence, structure and function. J Endocrinol. 2017;234:T1–T16.
Shibata S. Mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron. J Endocrinol. 2017;234:T35–47.
Chapman K, Holmes M, Seckl J. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93:1139–206.
Ruhs S, Nolze A, Hübschmann R, Grossmann C. Nongenomic effects via the mineralocorticoid receptor. J Endocrinol. 2017;234:T107–24.
Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172:R191–203.
Zennaro M-C, Boulkroun S, Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. J Endocrinol. 2015;224:R63–77.
McManus F, Sands W, Diver L, MacKenzie SM, Fraser R, Davies E, Connell JM. APEX1 regulation of aldosterone synthase gene transcription is disrupted by a common polymorphism in humans. Circ Res. 2012;111:212–9.
Tesch GH, Young MJ. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front Pharmacol. 2017;8:313.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.
DuPont JJ, Jaffe IZ. The role of the mineralocorticoid receptor in the vasculature. J Endocrinol. 2017;234:T67–82.
Jia G, Habibi J, Aroor AR, Hill MA, Yang Y, Whaley-Connell A, Jaisser F, Sowers JR. Epithelial sodium channel in aldosterone-induced endothelium stiffness and aortic dysfunction. Hypertension. 2018;72:731–8. HYPERTENSIONAHA.118.11339
Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;122:624–38. HYPERTENSIONAHA.118.11065
Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53–8.
Kolkhof P, Bärfacker L. Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125–40.
Bernhardt R. The potential of targeting CYP11B. Expert Opin Ther Targets. 2016;20:923–34. 14728222.2016.1151873
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.
Funder JW. Primary aldosteronism: the next five years. Horm Metab Res. 2017;49:977–83.
Miller WL. Steroidogenesis: unanswered questions. Trends Endocrinol Metab. 2017;28:771–93.
Acknowledgements
S.M.M., J.C.v.K. and E.D. are members of the ENS@T-HT EU-funded Horizon 2020 research and innovation project into hypertension and personalised treatments (► http://www.ensat-ht.eu).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
MacKenzie, S.M., Cat, A.N.D., van Kralingen, J.C., Davies, E. (2019). Aldosterone. In: Touyz, R., Delles, C. (eds) Textbook of Vascular Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-16481-2_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-16481-2_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16480-5
Online ISBN: 978-3-030-16481-2
eBook Packages: MedicineMedicine (R0)